Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | CCR8 | P51685 | 4/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17048459 | 0.87 | KDM4E (0.62) | KDM4EALDH1A1HPGDHTTGRIN2B | |
| SCHEMBL13176328 | 0.87 | CYP2C19 (0.51) | KDM4EALDH1A1HPGDHTTGRIN2B | |
| Hydrochloric Acid SCHEMBL2907770 | 0.86 | CYP2C19 (0.50) | KDM4EALDH1A1HPGDHTTGRIN2B | |
| SCHEMBL17048422 | 0.82 | CCR8 (0.66) | KDM4EALDH1A1HPGDHTTGRIN2B | |
| SCHEMBL17108223 | 0.82 | CCR8 (0.68) | KDM4EALDH1A1HPGDHTTGRIN2B | |
| SCHEMBL17099378 | 0.80 | ALDH1A1 (1.00) | KDM4EALDH1A1HPGDHTTLMNA | |
| SCHEMBL17055902 | 0.79 | GRIN2B (0.56) | KDM4EALDH1A1HPGDHTTGRIN2B | |
| SCHEMBL15635444 | 0.77 | CCR8 (0.56) | KDM4EALDH1A1HPGDHTTLMNA | |
| SCHEMBL17108225 | 0.76 | KDM4E (0.59) | KDM4EALDH1A1HPGDHTTGRIN2B | |
| SCHEMBL13779975 | 0.76 | TSHR (0.50) | KDM4EALDH1A1HPGDGRIN2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867244-B1 | 4-PYRAZIN-2-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2023-01-18 | — | — | EP | disclosed |
| EP-3867245-B1 | 4-PYRIMIDIN-5-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2022-12-07 | — | — | EP | disclosed |
| US-20210393644-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-11166958-B2 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-09 | — | — | US | disclosed |
| US-11155539-B2 | 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-10-26 | — | — | US | disclosed |
| US-20200123141-A1 | 4-Pyridinylmethyl-Morpholine Derivatives and the use thereof as Medicament | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-23 | — | — | US | disclosed |
| WO-2020079040-A1 | 4-PYRIMIDIN-5-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
| US-20200123140-A1 | 4-Pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-23 | — | — | US | disclosed |
| US-20200121691-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-23 | — | — | US | disclosed |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | KDM4E 2066/4885ALDH1A1 3556/4885HPGD 1110/4885 |
| US-11155539-B2 | 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | KDM4E 559/4885ALDH1A1 1678/4885HPGD 2006/4885 |
| US-20200121691-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | KDM4E 644/4885ALDH1A1 1285/4885HPGD 2599/4885 |
| US-20200123141-A1 | 4-Pyridinylmethyl-Morpholine Derivatives and the use thereof as Medicament | GRIN2A, GRIN2C, GRIN3A | KDM4E 559/4885ALDH1A1 1678/4885HPGD 2006/4885 |
| US-20200123140-A1 | 4-Pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2C, GRIN2A, GRIN3A | KDM4E 507/4885ALDH1A1 901/4885HPGD 2683/4885 |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | KDM4E 2066/4885ALDH1A1 3556/4885HPGD 1110/4885 |
| US-20210393644-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | KDM4E 644/4885ALDH1A1 1285/4885HPGD 2599/4885 |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | CACNA1B, CACNG6, SCN5A | KDM4E 2066/4885ALDH1A1 3556/4885HPGD 1110/4885 |
| US-11166958-B2 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | KDM4E 644/4885ALDH1A1 1285/4885HPGD 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.